Drug Delivery Systems
Overview
Section titled “Overview”Effective drug delivery is critical for peptide therapeutics, which often face challenges such as rapid enzymatic degradation, poor membrane permeability, and fast renal clearance. Modern delivery systems aim to improve bioavailability, extend half-life, and enable targeted delivery to specific tissues or cell types.
Delivery Methods Comparison
Section titled “Delivery Methods Comparison”| Method | Mechanism | Advantages | Limitations |
|---|---|---|---|
| PEGylation | Polymer conjugation increases hydrodynamic radius | Reduces renal clearance, extends half-life, improves stability | Potential immunogenicity, reduced bioactivity |
| Lipid Nanoparticles | Encapsulation in lipid bilayers for cellular uptake | Enables mRNA delivery, protects cargo, endosomal escape | Cold chain requirements, limited payload capacity |
| Cyclodextrins | Inclusion complexation enhances solubility | Improves aqueous solubility, oral bioavailability | Limited cavity size, variable binding affinity |
| Depot Formulations | Sustained release from biodegradable microspheres | Extended release (weeks to months), improved compliance | Burst release risk, complex manufacturing |
| Nasal Delivery | Bypasses BBB via olfactory/trigeminal pathways | Direct brain targeting, non-invasive, rapid onset | Mucociliary clearance, limited absorption area |
| Oral Delivery | Absorption enhancers (e.g., SNAC for semaglutide) | Patient preference, convenient administration | Low bioavailability, gastric degradation |
| Transdermal Patches | Permeation through skin layers (microneedle arrays) | Sustained delivery, avoids first-pass metabolism | Skin irritation, size limitations for large molecules |
| Antibody-Drug Conjugates | Peptide linked to monoclonal antibody for targeting | Selective delivery to cancer cells, reduced off-target effects | Complex synthesis, potential immunogenicity |
Key Considerations
Section titled “Key Considerations”PEGylation is one of the most widely used strategies for extending peptide half-life. By attaching polyethylene glycol chains, the hydrodynamic radius of the molecule increases, reducing glomerular filtration in the kidneys. Typical PEG sizes range from 5-40 kDa, with larger polymers providing longer circulation times but potentially reduced cellular uptake.
Lipid nanoparticles have gained prominence with mRNA vaccines (e.g., COVID-19). The lipid bilayer structure protects fragile nucleic acid payloads while enabling cellular uptake through endocytosis. Key lipid components include ionizable lipids, PEG-lipids, cholesterol, and helper phospholipids.
Route of Administration
Section titled “Route of Administration”The choice of delivery route depends on the therapeutic index, pharmacokinetic requirements, and patient population. Intravenous administration provides 100% bioavailability but requires clinical settings. Subcutaneous and intramuscular routes offer depot effects. Oral and nasal routes improve patient compliance but face significant bioavailability challenges for peptide therapeutics.